Electrical Impedance Myography and Ultrasound as Biomarkers of Duchenne Muscular Dystrophy (QED)
|ClinicalTrials.gov Identifier: NCT01491555|
Recruitment Status : Completed
First Posted : December 14, 2011
Last Update Posted : March 24, 2016
Researchers at Children's Hospital Boston Neurology Department invite children to participate in a new research study. Researchers are looking for boys ages 2 - 30 with Duchenne Muscular Dystrophy (DMD) and healthy boys ages 2 - 30 (without any nerve or muscle concerns) to serve as controls. The study is evaluating a new technique that will test nerve and muscle function. The testing is all pain free.
Children participating in the study will come in for 10 visits over two years. Visits will take place every month at first, then less often for the remaining visits. The tests for the study itself take approximately 2hours. If participants are interested or would like to learn more about the study, please call Lavanya Madabusi at 617-919-3554 or Lavanya.Madabusi@childrens.harvard.edu. All inquiries will be kept strictly confidential.
|Condition or disease|
|Duchenne Muscular Dystrophy|
|Study Type :||Observational|
|Actual Enrollment :||73 participants|
|Observational Model:||Case Control|
|Official Title:||Electrical Impedance Myography and Ultrasound as Biomarkers of Duchenne Muscular Dystrophy|
|Study Start Date :||April 2012|
|Actual Primary Completion Date :||September 2015|
|Actual Study Completion Date :||September 2015|
35 boys ages 2 through 30 with DMD
35 healthy boys ages 2 through 30
- The rate of decline of DMD patients versus normal subjects as assessed by EIM and quantitative ultrasound [ Time Frame: up to 45 months ]With the successful completion of this aim, the investigators will establish that alterations in both EIM and QUS provide meaningful surrogate measures of disease progression in DMD.
- The rate of decline of DMD patients versus normal subjects as assessed by handheld dynamometry, 6-minute walk, and other functional tests. [ Time Frame: up to 45 months ]With the successful completion of this aim, the investigators will establish that alterations in functional assessments may provide additional meaningful surrogate measures of disease progression in DMD.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01491555
|United States, Massachusetts|
|Children's Hospital Boston|
|Boston, Massachusetts, United States, 02115|
|Principal Investigator:||Basil Darras, MD||Boston Children’s Hospital|
|Principal Investigator:||Seward Rutkove, MD||Beth Israel Deaconess Medical Center|